Physician profile
Sanjay Jain
NPI 1063455780
$7,097.77
in general payments reported to CMS, 2019-2025
41 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,757 · 2020: $1,149 · 2021: $1,407 · 2022: $1,341 · 2023: $880 · 2024: $458 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,377.54 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,476.31 | 2019-2024 | Breztri, Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $855.93 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $653.32 | 2019-2022 | |
| Novo Nordisk INC | $596.49 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $399.18 | 2019-2024 | Austedo Xr, Austedo |
| Lilly USA, LLC | $340.99 | 2019-2023 | Mounjaro, Jardiance |
| Ironshore Pharmaceuticals INC. | $304.96 | 2019-2023 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $272.23 | 2019-2022 | |
| Astellas Pharma US INC | $243.18 | 2024-2025 | Veozah |
| Sunovion Pharmaceuticals INC. | $195.41 | 2019-2020 | |
| Lundbeck LLC | $167.48 | 2020-2024 | Rexulti |
| Abbvie INC. | $147.46 | 2021-2022 | |
| Alkermes, INC. | $143.71 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $138.82 | 2020-2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $129.88 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.